Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.
Kara Swisher, Recode executive editor, shares her take on the Theranos board, calling it "the most unusual board in Silicon Valley."
Jim Cramer says investors need to be careful in high-risk cancer immunotherapy stocks.
CNBC's Meg Tirrell speaks to Brent Saunders, Allergan CEO, about the drug industry's new era under a Trump presidency.
CNBC's Meg Tirrell speaks to Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, about Trump's effect on biotech, drug pricing and the study against high cholesterol.
CNBC's Meg Tirrell speaks to Robert Nelsen, ARCH Venture Partners founder, about Trump's potential impact on the drug industry, and the future of biotech.
Sources say the Valeant-Takeda deal is "all but dead." CNBC's Scott Wapner reports the details, as well as how the market is reacting to this news.
Christopher Weaver, Wall Street Journal reporter, discusses Theranos' "smart money" investors, as well as the company's recent challenges.
Jason Kolbert, Maxim Group, and Les Funtleyder, ESquared, discuss biotech opportunities in Cuba post-Castro.
Thernos is being sued for alleged fraud by Robert Colman, Robertson Stephens co-founder. CNBC's Sue Herera reports.
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
Robyn Karnauskas, Citi Research lead biotech analyst, weighs in on the drop in Juno Therapeutics following the company's study halt.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
If they're right, the average lifespan of 79 years will be a thing of the past, and humans could live for decades longer.
CNBC's Meg Tirrell reports the latest surrounding the Valeant and Philidor controversy. CNBC's Kate Kelly and David Winters, Wintergreen Advisors CEO, weigh in on Valeant's stock.
Amgen's migraine drug meets its clinical trial goal. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell on the latest regarding data on how a Puma drug designed to treat breast cancer shows gastric side effects.
Top-ranking health care analyst & senior analyst at Evercore ISI, Umer Raffat discusses biotech stocks on Power Lunch.
Les Funtleyder, ESquare portfolio manager, shares his take on the healthcare sector amid a Trump presidency.
CNBC's Meg Tirrell reports details from Mylan's earnings conference call. The "Fast Money" traders weigh in.